Does Arkansas Medicaid Cover Wegovy or Zepbound? The Three Routes That Remain

No. Arkansas Medicaid does not cover Wegovy, Zepbound or any other drug prescribed only for weight loss, and its prior authorization criteria, revised October 1, 2026, say so on both drugs’ pages.^[1] As of November 2026 it does cover Wegovy with prior authorization for people with heart disease and a BMI of at least 27 or for the liver disease MASH, and Zepbound for moderate to severe sleep apnea after six months on CPAP.^[1]

Is there any Arkansas Medicaid route for weight loss alone?

No, and there is no exception process for weight loss alone. The Wegovy page of the state’s criteria opens with a note ruling out drugs used only to lose weight, and the Zepbound page repeats it.^[1] Each lists “requested for weight loss only” as a reason to deny.^[1] When Wegovy tablets were added in May 2026, the provider memo repeated that the pharmacy program “does not cover medications for weight loss.”^[2] The state’s quarterly newsletters, most recently in October 2026, give the newest GLP-1 pill, Foundayo, a one-line verdict: weight loss is not covered.^[3]

Under federal law, every state may leave weight-loss drugs out of Medicaid.^[10] Arkansas lawmakers had a chance to change that in 2025 and chose not to. Act 628 requires Medicaid to pay for bariatric surgery and the care around it, then says in subsection (c) that nothing in it obliges the program to pay for glucose-lowering injections or other weight-loss prescriptions.^[4] So an Arkansan with severe obesity can get surgery covered but not a GLP-1 for the same diagnosis.

When does Arkansas Medicaid cover Wegovy?

Wegovy has two covered uses in Arkansas, both drawn from its FDA label: cutting the odds of a heart attack, stroke or cardiovascular death for adults who already have heart disease, and treating MASH with moderate to advanced liver scarring.^[8][1] The state’s tests go further than the label in several places.

The smoking rule on the heart route catches people by surprise. A current smoker must have started a cessation program before Wegovy can be approved.^[1] The prescriber also has to send chart notes, an HbA1c and lipid panel, baseline weight and waist size, blood pressure and heart rate, and an attestation that the patient was counseled on diet and activity.^[1] Wegovy tablets follow the heart-risk criteria only, since the MASH section is labeled for the injection.^[1][2]

The MASH route has a diabetes twist. A person with both type 2 diabetes and MASH is sent to a GLP-1 approved for diabetes rather than Wegovy.^[1] For background on what the liver trial showed, see our guide to GLP-1s and MASH.

Does Arkansas Medicaid cover Zepbound for sleep apnea?

Yes, but the bar is high. The label covers moderate to severe sleep apnea in adults with obesity.^[9] Arkansas adds a second condition tied to weight, half a year in a structured weight program, and at least six months of documented CPAP or BiPAP use that has not brought the apnea-hypopnea index below 15.^[1] In practice that means a person who tolerates CPAP well enough to use it every night, yet still has moderate apnea on it. Someone who could not tolerate CPAP has no stated route, because skipping nightly CPAP is one of the listed grounds for denial.^[1]

The criteria page is titled for the 10 mg and 15 mg strengths, the sleep apnea maintenance doses on the label, which starts everyone at 2.5 mg.^[1][9] The page does not say how the starting strengths are handled, so ask the pharmacy help desk before the first fill. Our guide to Zepbound for sleep apnea explains the trial results behind this use.

Does Arkansas Medicaid cover Ozempic or Mounjaro for diabetes?

Yes, but they are not the drugs the state prefers. Trulicity and brand-name Victoza are the preferred GLP-1s for diabetes. Ozempic, Rybelsus, Mounjaro and generic liraglutide are non-preferred and need prior authorization.^[1] A preferred drug passes the automatic check when the pharmacy record shows a type 2 diabetes diagnosis plus a metformin claim or an HbA1c of 9 or higher in the past 186 days, or a diagnosis of atherosclerotic heart disease.^[1] None of these is approved for weight loss in Arkansas Medicaid. The October 2026 newsletter lists Mounjaro among drugs whose prior authorization criteria the state’s drug review board would take up on October 21, 2026; as of November 6, 2026 the posted criteria still list it only as a non-preferred diabetes drug.^[3][1]

Does it matter if you are in ARHOME or a PASSE?

It can. ARHOME, the program for many adults who qualify through Medicaid expansion, uses Medicaid money to buy private coverage from Blue Cross Blue Shield or Ambetter.^[6] Those members are still on Medicaid, but the carrier on their card handles their benefits, so they should ask that carrier which drug list and criteria apply to them. PASSE plans, which serve people with significant behavioral health needs or developmental disabilities, include pharmacy, and the state tells prescribers to send PASSE drug questions to the member’s PASSE.^[7][2] The criteria in this article govern the state’s own pharmacy program.

What about children and teens?

Wegovy’s label includes obesity treatment from age 12, but Arkansas covers no weight-loss use at any age, and its criteria have no pediatric obesity page for a GLP-1.^[8][1] Federal law does require Medicaid to provide necessary treatment found through child health screening for people under 21, even when the state plan does not cover it.^[11] We found no Arkansas document that applies that rule to GLP-1s. A family that gets a flat denial for a teen can ask in writing for a medical necessity review under EPSDT, the federal child-health benefit.

How do you request approval or appeal a denial in Arkansas?

• Requests. Prescribers submit through CoverMyMeds or by fax to the state pharmacy unit at 800-424-5851, the number printed on both the Wegovy and Zepbound pages. The Prime help desk is 800-424-7895.^[1]
• Paperwork. Each route lists what to send: chart notes, labs, BMI and weight, and route-specific proof such as a sleep study with the CPAP usage report or the fibrosis results.^[1]
• Appeals. For a denied Medicaid service, the state says to send a letter asking for an administrative hearing, and warns that a late request will be denied.^[5] Its appeals page gives no day count for this kind of denial, so use the deadline printed on your notice and file promptly.

An appeal works best when the denial concerns a covered use, such as a missing CPAP report. It has nothing to work with when the request rests on weight alone. Our walkthrough of prior authorization and appeals covers what makes a strong file, and the state Medicaid GLP-1 checker shows how Arkansas compares with other states.

What are the options without Medicaid coverage?

Paying cash is the main one. Lilly’s savings card for insured patients excludes anyone enrolled in Medicaid, so it will not lower the price.^[12] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound.^[12][13] Read each offer’s terms on government-program enrollment before you sign up. Our list of the cheapest GLP-1 routes without insurance compares them, and the Arkansas page lists sellers that ship to the state.